OpenAI launches GPT-Rosalind to support drug discovery research

OpenAI has released an early research preview of GPT-Rosalind, an AI model aimed at life sciences research; the model will first be available to a limited set of business customers, including Amgen and Moderna.

OpenAI has introduced an early version of a new AI model called GPT-Rosalind that is focused on life sciences. The model is described as a tool to help researchers analyze large data sets and to assist in translating scientific findings toward healthcare applications. OpenAI will make the model available initially as a limited research preview to selected business customers. The announcement comes as other technology firms are also applying AI to healthcare and scientific research. Key details: - GPT-Rosalind is presented as an AI model aimed at accelerating drug discovery and life sciences research. - The model will be released as a limited research preview to selected business customers, with Amgen and Moderna named among those customers. - The article places this release within a broader industry trend, mentioning companies such as Anthropic and Alphabet’s DeepMind, and citing past work like AlphaFold. - OpenAI notes that AI is not yet able to independently create new treatments and highlights safety concerns about possible misuse. - OpenAI says it has added safeguards, including systems to flag potentially dangerous activity and limits on model use; the article also mentions analysts’ commentary about Alphabet’s stock. Summary: The release represents a step toward applying large AI models to biomedical research, with early access given to industry partners. OpenAI emphasizes safety and has implemented guardrails. Further assessment will come from the limited research preview and subsequent collaborations.